The association between vitamin C and vitamin E supplement use before hematopoietic stem cell transplant and outcomes to two years
| Autor: | Barbara Bruemmer, Robert P. Witherspoon, Aker Sn, Carrie L Cheney, Ruth E. Patterson |
|---|---|
| Rok vydání: | 2003 |
| Předmět: |
Adult
Male medicine.medical_specialty Adolescent medicine.medical_treatment Breast Neoplasms Ascorbic Acid Antioxidants Disease-Free Survival Cohort Studies Breast cancer Internal medicine Leukemia Myelogenous Chronic BCR-ABL Positive Epidemiology medicine Humans Vitamin E Risk factor Proportional Hazards Models Acute leukemia Nutrition and Dietetics business.industry Hematopoietic Stem Cell Transplantation Cancer Middle Aged Precursor Cell Lymphoblastic Leukemia-Lymphoma medicine.disease Ascorbic acid Surgery Leukemia Myeloid Acute Dietary Supplements Female business Food Science Cohort study |
| Zdroj: | Journal of the American Dietetic Association. 103(8) |
| ISSN: | 0002-8223 |
| Popis: | Objective To examine the prevalence of supplement use in persons before receiving hematopoietic stem cell transplant (HSCT) and the association of select supplements with outcomes. Design This observational cohort study included a questionnaire on supplement use before HSCT. Nonrelapse mortality, recurrence/relapse, and mortality or relapse (the inverse of disease-free survival) were followed to two years. Subjects/Setting Persons receiving HSCT at the Fred Hutchinson Cancer Research Center between September 1994 and December 1997 were eligible (N=1,182). Statistical Analyses Performed Descriptive statistics and univariate and Cox regression analyses were conducted. Results Sixty-six percent of patients used supplements (31% vitamin C, 19% vitamin E, and 20% herbs or others preparations). Vitamin C at ≥500 mg/day was inversely associated with recurrence among persons with breast cancer (RR=0.11; 95% CI, 0.02-0.89; P =.03). However, among persons with acute leukemia, vitamin C at ≥500 mg/day was positively associated with nonrelapse mortality (RR=2.25; 95% CI, 1.33-3.83; P =.01) and mortality or relapse (RR=1.63; 95% CI, 1.09-2.44; P =.01), respectively. Vitamin E at ≥400 IU/day was positively associated with mortality or relapse (RR=1.77; 95% CI, 1.06 −2.96; P =.02). Applications/Conclusions Though this work was observational, the results suggest supplemental vitamin C before therapy may be beneficial in persons with breast cancer but both vitamin C and vitamin E may increase risk in persons with acute leukemia receiving HSCT. Practitioners should document supplement use in subjects receiving therapy for cancer. J Am Diet Assoc. 2003;103:982-990. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect